Clinical Trial

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-03-28; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2025-05-15
Trial Details
NCT Number NCT06911424
Lead Sponsor Baxis Pharmaceuticals, Inc.
Conditions Bacterial Conjunctivitis
Enrollment 400 participants
Start Date 2025-03-21
Primary Completion 2026-03-16 (estimated)
Study Completion 2026-03-23 (estimated)
Updated on ClinicalTrials.gov 2026-03-17